Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
08
2022
accepted:
10
12
2022
entrez:
6
1
2023
pubmed:
7
1
2023
medline:
11
1
2023
Statut:
epublish
Résumé
We evaluated the association of disease outcome with T cell immune-related characteristics and T cell receptor (TCR) repertoire in malignant ascites from patients with high-grade epithelial ovarian cancer. Ascitic fluid samples were collected from 47 high-grade epithelial ovarian cancer patients and analyzed using flow cytometry and TCR sequencing to characterize the complementarity determining region 3 TCR β-chain. TCR functions were analyzed using the McPAS-TCR and VDJ databases. TCR clustering was implemented using Grouping of Lymphocyte Interactions by Paratope Hotspots software. Patients with poor prognosis had ascites characterized by an increased ratio of CD8+ T cells to regulatory T cells, which correlated with an increased productive frequency of the top 100 clones and decreased productive entropy. TCRs enriched in patients with an excellent or good prognosis were more likely to recognize cancer antigens and contained more TCR reads predicted to recognize epithelial ovarian cancer antigens. In addition, a TCR motif that is predicted to bind the TP53 neoantigen was identified, and this motif was enriched in patients with an excellent or good prognosis. Ascitic fluid in high-grade epithelial ovarian cancer patients with an excellent or good prognosis is enriched with TCRs that may recognize ovarian cancer-specific neoantigens, including mutated TP53 and TEAD1. These results suggest that an effective antigen-specific immune response in ascites is vital for a good outcome in high-grade epithelial ovarian cancer.
Identifiants
pubmed: 36607962
doi: 10.1371/journal.pone.0279590
pii: PONE-D-22-22421
pmc: PMC9821423
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279590Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright: © 2023 Yoshida-Court et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Genet. 2020 Jun;52(6):615-625
pubmed: 32393859
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
Bioinformatics. 2004 Jun 12;20(9):1453-4
pubmed: 14871861
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Nat Biotechnol. 2020 Oct;38(10):1194-1202
pubmed: 32341563
Int J Cancer. 2010 Jun 1;126(11):2635-43
pubmed: 19856313
Front Immunol. 2019 Jan 11;9:3156
pubmed: 30687337
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Mol Clin Oncol. 2014 Mar;2(2):212-218
pubmed: 24649335
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W281-7
pubmed: 22638583
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366
Eur J Immunol. 2012 Nov;42(11):2834-9
pubmed: 23108932
Gynecol Oncol. 2018 Aug;150(2):239-246
pubmed: 29807697
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
Immunotherapy. 2018 Jul;10(9):769-778
pubmed: 29926750
Mol Cancer. 2016 Oct 27;15(1):67
pubmed: 27784305
Mol Oncol. 2020 Oct;14(10):2660-2677
pubmed: 32412676
BMC Cancer. 2019 Nov 25;19(1):1140
pubmed: 31766991
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Front Microbiol. 2018 Mar 07;9:297
pubmed: 29563898
Oncol Lett. 2018 Sep;16(3):3949-3954
pubmed: 30128013
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Haematologica. 2008 Feb;93(2):193-200
pubmed: 18223287
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Transl Cancer Res. 2016 Dec;5(6):650-663
pubmed: 30613473
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Cell Cycle. 2012 May 1;11(9):1773-81
pubmed: 22510613
J Cancer. 2019 Feb 23;10(6):1434-1443
pubmed: 31031853
Cancer. 2006 Dec 15;107(12):2866-72
pubmed: 17099880
BMC Cancer. 2020 May 4;20(1):375
pubmed: 32366230
Clin Cancer Res. 1995 Oct;1(10):1223-32
pubmed: 9815916
Bioinformatics. 2004 Nov 22;20(17):3246-8
pubmed: 15180930
Nucleic Acids Res. 2018 Jan 4;46(D1):D419-D427
pubmed: 28977646
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
BMC Cancer. 2015 Jul 01;15:492
pubmed: 26122176
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Cancers (Basel). 2022 Sep 01;14(17):
pubmed: 36077825
PLoS One. 2014 Nov 04;9(11):e109575
pubmed: 25369529
Oncoimmunology. 2018 Nov 16;8(2):e1535730
pubmed: 30713791
Nucleic Acids Res. 2012 Sep 1;40(17):e131
pubmed: 22638576
PLoS One. 2019 Apr 25;14(4):e0215381
pubmed: 31022191
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Biometrics. 2007 Dec;63(4):1031-7
pubmed: 17425640
J Clin Invest. 1990 Sep;86(3):851-5
pubmed: 2394835
Arch Gynecol Obstet. 2019 Feb;299(2):515-523
pubmed: 30415435
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Front Immunol. 2020 Oct 22;11:565096
pubmed: 33193332
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Bioinformatics. 2017 Sep 15;33(18):2924-2929
pubmed: 28481982
Nat Biotechnol. 2018 Nov 12;:
pubmed: 30418433
Proc Natl Acad Sci U S A. 2016 May 24;113(21):6005-10
pubmed: 27152024
BMC Cancer. 2012 Apr 03;12:134
pubmed: 22471961
Gene. 2020 Apr 20;735:144402
pubmed: 32004669
Oncogene. 2019 Apr;38(16):2885-2898
pubmed: 30568223
Cell Mol Life Sci. 2018 Feb;75(3):509-525
pubmed: 28956065
Am J Reprod Immunol. 2020 Sep;84(3):e13284
pubmed: 32524661